General Information of Drug Transporter (DT)
DT ID DTD0009 Transporter Info
Gene Name SLC22A3
Transporter Name Organic cation transporter 3
Gene ID
6581
UniProt ID
O75751
Post-Translational Modification of This DT
Overview of SLC22A3 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-N-glycosylation X-Phosphorylation X: Amino Acid

N-glycosylation

  Asparagine

          4 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC22A3 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

72

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC22A3 Asparagine 72 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC22A3 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

99

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC22A3 Asparagine 99 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC22A3 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

119

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC22A3 Asparagine 119 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC22A3 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

322

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC22A3 Asparagine 322 has the potential to affect its expression or activity.

Phosphorylation

  Serine

          4 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC22A3 [2]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

78

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC22A3 Serine 78 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC22A3 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

334

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC22A3 Serine 334 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC22A3 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

337

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC22A3 Serine 337 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC22A3 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

537

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC22A3 Serine 537 has the potential to affect its expression or activity.

  Threonine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC22A3 [3]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

327

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC22A3 Threonine 327 has the potential to affect its expression or activity.

  Tyrosine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Potentially affecting the transporter [5] , [6]

Role of PTM

On/Off Switch

Modified Residue

Tyrosine

Modified State

Tyrosine kinase inhibitors (Pazopanib)

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Phosphorylation at SLC22A3 Tyrosine (i.e. Tyrosine kinase inhibitors (Pazopanib)) have been reported to have the potential to affect the transporter.

  PTM Phenomenon 2

Have the potential to influence SLC22A3 [3]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

318

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC22A3 Tyrosine 318 has the potential to affect its expression or activity.
References
1 dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: S22A3_HUMAN)
2 Synthesizing Signaling Pathways from Temporal Phosphoproteomic Data. Cell Rep. 2018 Sep 25;24(13):3607-3618.
3 Mass spectrometric phosphoproteome analysis of small-sized samples of human neutrophils. Clin Chim Acta. 2015 Dec 7;451(Pt B):199-207.
4 Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res. 2016 Oct;14(10):1019-1029.
5 Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res. 2016 Aug;110:89-95.
6 A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016 Mar 16;7:10880.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.